Blood · 2017 · 143 citations · 10 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDrug Efficacy AssessmentEfficacy EvaluationMedication AdherencePatient AdherenceTreatment AdherenceTreatment EffectivenessAdherenceAdherence To TherapyPersistence To TherapyTherapeutic Efficacy Assessment
status. Of 79 patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a missed-dose event was 18.7 days (range, 8-56). Patients missing ≥8 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously treated CLL. The trial was registered at www.clinicaltrials.gov as #NCT01578707.
10
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text